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Popovic´.1068 The Journal of Thoracic and CardObjective: We evaluated the capability of the Myocor Coapsys
device (Myocor, Inc, Maple Grove, Minn) to reduce functional
mitral regurgitation in a canine model of dilated cardiomyopathy.
Methods: Functional mitral regurgitation with heart failure was
induced in 7 dogs by rapid ventricular pacing. The Coapsys device,
which consists of anterior and posterior epicardial pads connected
by a subvalvular chord, was then implanted. Heart failure was
maintained by continued pacing for 8 weeks. Hemodynamic and
echocardiographic measurements were performed at pre- and post-
sizing and after 8 weeks. The Coapsys subvalvular chord was cut to
verify that maintenance of valve competency was due to the device.
Results: All implants were performed off-pump without atriotomy. Mitral regurgi-
tation was reduced in all animals; mean mitral regurgitation grade was reduced from
2.9 0.7 to 0.7 0.8 (P .00005) and was maintained at 0.8 0.8 after 8 weeks,
without hemodynamic compromise or structural damage to the mitral valve. Mitral
regurgitation returned to 3.6  0.8 (P  .102 versus presizing) after cutting the
Coapsys subvalvular chord.
Conclusion: The Coapsys device consistently and chronically reduced functional
mitral regurgitation. This device is in clinical trials in the United States.
Functional mitral regurgitation (MR) occurs with a structurally normalvalve as a complication of left ventricular (LV) dysfunction, and as aresult, almost half the patients with LV dysfunction have at leastmoderate MR.1 Recently, studies revealed that changes in the 3-di-mensional relationships between the LV and mitral apparatus (mitralannular dilatation and papillary muscle displacement) induce func-
tional MR.2-8 Based upon this information, 3-dimensional restoration of mitral valve
(MV) geometry is an appropriate means to treat patients with functional MR. A
novel device, the Coapsys Annuloplasty System (Myocor, Inc, Maple Grove, Minn),
was developed to treat functional MR. The Coapsys device is designed to correct
valve dysfunction without requiring the use of cardiopulmonary bypass (CPB) or an
open-heart access method. This study was conducted to evaluate the acute and
achi, Kopcak,
rthy, Thomas,chronic effects of the Coapsys device on MR in a canine model of functional MR.
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PMaterial and Methods
The Coapsys Concept and Coapsys Design
The Coapsys concept and Coapsys device have been previously
reported.9 Briefly, the Coapsys device was developed to treat
patients with Carpentier type I (normal) or type IIIb (restrictive)
valve leaflet motion.10 The Coapsys device consists of an epicar-
dial posterior pad, epicardial anterior pad, and subvalvular chord.
The 2 pads are located on the surface of the heart with the
load-bearing subvalvular chord passing through the ventricle (Fig-
ure 1). The posterior pad has 2 heads, such that the annular head
imparts shape change directly to the mitral annulus when the
anterior and posterior pads are drawn together. The papillary head
provides leverage at midpapillary muscle level to change the
papillary muscle position (Figure 2). The device is tightened,
under echocardiographic visualization on the beating heart, until
MR is significantly reduced or eliminated. The polyester-covered
anterior pad is adjustable, utilizing a deployable pin mechanism,
and is fixed to the subvalvular chord after sizing the device during
the procedure.
In Vivo Study
This study was approved by the Cleveland Clinic’s Institutional
Animal Care and Use Committee, and all animals received humane
care in compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources, National Research Council, and published by the
National Academy Press, revised 1996.
Animal Model
Among several potential MR models, chronic rapid ventricular
pacing was chosen in this study because the hemodynamic and
echocardiographic changes are very similar to those found in
human functional MR.11 Also, rapid ventricular pacing produces
heart failure,4,11-13 which is a common comorbidity among this
patient group.
The methodology of inducing and maintaining the model has
been reported.12 Seven adult mongrel dogs (body weight 25.0 
1.1 kg) were paced via the right ventricular (RV) transvenous lead
Figure 1. The Coapsys device consists of an epicardial
chord (left). The 2 pads are located on the surface of
through the ventricle (right). AML, Anterior mitral leaflusing rapid asynchronous ventricular pacing at 230 beats per
The Journal of Thoracicminute for an average of 31  4 days to induce functional MR
with heart failure. No medication for heart failure, including di-
uretics, was given during the induction phase. At the end of the
induction phase, the pacemaker rate was temporarily reduced to
demand mode at 30 beats per minute so that the animal would
resume normal sinus rhythm, and transthoracic 2-dimensional
(2-D) echocardiograms were obtained to evaluate the progression
of cardiac remodeling, the reduction of LV function, and devel-
opment of MR and tricuspid regurgitation (TR; graded on a scale
from 0 to 4). If MR was equal to or more than 2 at the
presizing data point then plans were made for Coapsys implanta-
tion.
Coapsys Implant Surgery
On the date of study, the pacemaker was again reduced to demand
mode, and the animal was anesthetized with thiopental (15 mg/kg)
and intubated. The anesthesia was maintained with isoflurane
(0.5%-2.5%). The following hemodynamic and echocardiographic
measurements were taken as the baseline closed-chest data point.
A catheter with 2 Millar pressure sensors (Model SPC-562; Millar
Instruments, Inc, Houston, Tex) was placed via the carotid artery
to record aortic (AoP) and LV (LVP) pressures. A thermistor-tip
balloon catheter (Criticath SP5507 TD catheter; Becton Dickinson
Infusion Therapy System Inc, Sandy, Utah) was passed from the
jugular vein to the pulmonary artery to monitor the pulmonary
artery pressure and the central venous pressure. Cardiac output
(COSG) and stroke volume (SVSG) were measured by thermodilu-
tion method. Hemodynamic indices were digitized in real time at
a sampling rate of 200 Hz with a data acquisition system (Power-
Lab; AD Instruments, Inc, Mountain View, Calif) and stored on a
hard disk for subsequent analysis. Changes in LV volumes were
assessed before and after sizing the Coapsys device by a 3-dimen-
sional (3-D) ultrasound system (Volumetrics Medical Imaging Inc,
Durham, NC). Subsequently, LV end-diastolic (LVEDV) and end-
systolic (LVESV) volumes were determined by rotated apical
6-plane views with multiplanar Simpson method.14 Stroke work
(stroke work [LVEDV LVESV] [LV end-systolic pressure
 LV end-diastolic pressure]  0.0136) and ejection fraction
rior pad, an epicardial posterior pad, and a subvalvular
eart with the load-bearing subvalvular chord passing
ML, posterior mitral leaflet.ante
the h(ejection fraction  [LVEDV  LVESV]/LVEDV  100) were
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TR, and aortic regurgitation (AR) by color Doppler imaging. The
mitral annular septal-lateral (S-LMA) dimension was measured
using the long-axis view and the mitral annular commissure-
commissure (C-CMA) dimension was measured using the 2-cham-
ber view at end-diastole and end-systole. The LV cross-sectional
dimensions in septal-lateral (S-LLV) and commissure-commissure
(C-CLV) planes were measured at midpapillary muscle level. MR
volume and effective regurgitant orifice area (EROA) were calcu-
lated using the continuity equation.15 MR jet area, the ratio of MR
jet area to left atrial area (MR/LA ratio), annular area, and peak
MV pressure gradient were also measured. A sternotomy was
performed and the chest was opened. Just prior to opening the
chest, a continuous infusion of lidocaine was started at 1 mg/kg/h
to prevent ventricular arrhythmias. A 14-mm Transonic flow probe
(model no. 14A165, Transonic Systems Inc, Ithaca, NY) was
placed on the ascending aorta and connected to a flow meter
(Model T106, Transonic Systems Inc) to measure cardiac output
Figure 2. The annular head of the posterior pad was lo
septal-lateral dimension of the mitral annulus. The
midpapillary level to change the papillary muscle posit
leaflet; PML, posterior mitral leaflet; S-LMA1, mitral a
septal-lateral dimension 2; S-LLV1, left ventricular septa
dimension 2.(COFP) and stroke volume (SVFP). A Millar catheter (model SPC-
1070 The Journal of Thoracic and Cardiovascular Surgery ● Apr350; Millar Instruments, Inc) was inserted into the LA to monitor
LA pressure (LAP).
The Coapsys device was surgically implanted. The appropriate
sites for the Coapsys device placement were identified through a
combination of external landmarks and 2-D echocardiographic
visualization of internal structures to avoid compromise of papil-
lary muscles, mitral apparatus, or main coronary artery branches.
The position of the posterior pad was approximately 2.5 cm from
the atrioventricular groove and midway between the papillary
muscles. The anterior pad was positioned at the apical edge of the
base of the RV outflow tract and approximately 2 cm to the RV
side of the left anterior descending artery. Following site identifi-
cation, the delivery instrument was fixed to the heart utilizing
vacuum assistance. A needle assembly, consisting of a stylet and
hollow catheter, was then inserted through the delivery instrument
from the anterior wall. Following passage of the needle assembly,
the stylet was removed and the subvalvular chord threaded through
the catheter and pulled through both walls. The subvalvular chord
d at the mitral annular level and worked to reduce the
llary head of the posterior pad was located at the
ward the left ventricular septum. AML, Anterior mitral
ar septal-lateral dimension 1; S-LMA2, mitral annular
eral dimension 1; S-LLV2, left ventricular septal-lateralcate
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ion to
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Pthe LV wall. The anterior pad was inserted over the anterior side
of the subvalvular chord. Hemodynamic and echocardiographic
measurements were recorded as the presizing data point. Follow-
ing Coapsys device placement, the subvalvular chord leader was
then secured to the sizing instrument. The Coapsys device was
then tightened by drawing the posterior leaflet and annulus toward
the anterior leaflet. The deployment level was selected when MR
was minimized or eliminated as assessed by color Doppler images.
The device size (epicardial to epicardial measurement) was ob-
tained as the presizing and postsizing measurements (measured as
percent linear reduction from presizing measurement). The Coap-
sys device was fixed at the deployment level. Hemodynamic and
echocardiographic measurements were repeated as the postsizing
data point. The chest was then closed in the standard fashion.
Postoperative analgesics and antibiotics were administrated,
but no anticoagulants or antiplatelet drugs were administrated. To
avoid the natural recovery of the LV and MV performance after
cessation of pacing, rapid pacing at 190 beats per minute was
started 3 days after surgery and maintained for 8 weeks until the
terminal study.12 Each dog was given furosemide (40 mg/d) during
the postoperative period. One dog was unable to eat or drink after
the implantation surgery due to severe heart failure. This dog was
treated with hyperalimentary therapy and discontinued pacing for
1 week (data from this animal were included in all data points).
Another dog died on postoperative day 14 due to an ascending
aortic rupture, which was induced by the chronically implanted
aortic flow probe (data from this animal were included in baseline
closed-chest, presizing, and postsizing data points).
Terminal Study
Eight weeks after the Coapsys implantation, the animals were
again anesthetized and hemodynamic monitoring lines were re-
placed. Hemodynamic and echocardiographic measurements were
performed as terminal closed-chest data point. After obtaining all
data, the chest was opened, and hemodynamic and echocardio-
graphic measurements were performed as terminal open-chest data
point. Under 2-D echocardiographic guidance, the Coapsys sub-
valvular chord was cut utilizing a laparoscopic scissor introduced
into the LV through a purse-string suture on the apex to verify that
maintenance of the valve competency was due to the device
(model verification). Hemodynamic and echocardiographic mea-
surements were again performed and recorded as subvalvular
chord-cut data point.
All animals were put to death and complete autopsies were
performed. The hearts were excised, and the device’s relationship
to the coronary vessels and intraventricular structures was exam-
ined.
Statistical Analysis
Data were expressed as mean  standard deviation. For the acute
evaluation, there was 1 pair of data: presizing and postsizing. For
the chronic evaluation, there were 3 pairs of data: closed-chest
(baseline and terminal) and open-chest (presizing and terminal
open-chest and postsizing and terminal open-chest). For the model
verification, there were 2 pairs of data: terminal open-chest and
subvalvular chord-cut, and presizing and subvalvular chord-cut. A
paired t test was used for each paired data.
The Journal of ThoracicResults
All Coapsys device implantations were performed on beat-
ing hearts without the aid of CPB. The hemodynamic data
during the implantation procedure were stable in all cases.
The mean device sizes at presizing and postsizing were 6.9
 0.6 cm and 5.0 0.2 cm, respectively. The mean percent
linear reduction from presizing measurement was 26.4% 
6.9%.
Table 1 summarizes the echocardiographic findings. By
2-D echocardiography, MR was reduced in all animals. MR
decreased from 2.9  0.7 at presizing to 0.7  0.8 at
postsizing (P  .00005) and from 2.5  0.8 at baseline
closed-chest to 0.8  0.8 at terminal closed-chest (P 
.002). MR increased from 0.8 0.8 at terminal closed-chest
to 1.9 0.7 at terminal open-chest (P .041). MR returned
to 3.6  0.8 after cutting the Coapsys subvalvular chord (P
 .001 vs terminal open-chest). There was no significant
difference in MR grade between presizing and subvalvular
chord-cut (Figure 3). End-diastolic and end-systolic S-LMA
dimensions decreased significantly at postsizing and termi-
nal closed-chest and increased significantly after cutting the
subvalvular chord (Figure 4). The C-CMA dimensions were
unchanged (Figure 5). End-diastolic and end-systolic S-LLV
dimensions also decreased significantly at postsizing and
terminal closed-chest and increased significantly after cut-
ting the subvalvular chord. The end-diastolic C-CLV dimen-
sion at postsizing increased significantly and end-systolic
C-CLV dimension decreased significantly after cutting the
subvalvular chord. There were no significant differences in
S-LLV and C-CLV dimensions between presizing and termi-
nal subvalvular chord-cut. At terminal open-chest, both
S-LMA and S-LLV dimensions decreased significantly com-
pared with those at presizing and increased significantly
compared with those at postsizing. There were significant
decreases in EROA and MR volume between presizing and
postsizing and baseline closed-chest and terminal closed-
chest. EROA and MR volume increased from terminal
closed-chest to terminal open-chest (P .048 and P .028,
respectively) and from terminal open-chest to subvalvular
chord-cut (P  .023 and P  .054, respectively). MR jet
area and MR/LA area ratio improved after the Coapsys
implantation and was maintained for 8 weeks. Annular area
decreased from 4.7  0.6 cm2 at presizing to 3.3  0.5 cm2
at postsizing; P  .0003). Peak MV pressure gradient was
unchanged and revealed no mitral stenosis. There were no
significant changes in TR and AR.
By 3-D echocardiographic calculation, LVEDV (70 
28 mL to 46 19 mL; P .013) and LVESV (54 23 mL
to 30  20 mL; P  .016) decreased significantly at
postsizing. There was no significant change in LVEDV or
LVESV between baseline closed-chest and terminal closed-
chest. LVEDV and LVESV significantly decreased from
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Cardiopulmonary Support and Physiology Inoue et al
CSP
terminal closed chest to terminal open chest (P  .021 and
P  .01, respectively). After cutting of the Coapsys sub-
valvular chord, LVEDV increased significantly (58  12
mL to 65  10 mL; P  .008).
Despite the significant decreases in LV volumes, there
were no significant changes in COFP (1.71  0.55 L/min to
1.63  0.49 L/min; P  .144) or SVFP (19.2  8.3 mL to
18.4 7.7 mL; P .196) between presizing and postsizing.
There were no significant changes in COSG and SVSG
chronically. The mean AoP (77  20 mm Hg to 73  18
mm Hg; P  .011) and systolic LVP (91  20 mm Hg to
86  18 mm Hg; P  .012) decreased slightly but statisti-
TABLE 1. 2-D and 3-D echo findings
Baseline
closed-
chest
(n  7)
Im
Presizing
(n  7)
2-D echo findings
MR (grade) 2.5 0.8 2.9 0.7
TR (grade) 2.4 0.9 2.6 1.4
AR (grade) 0.7 0.8 1.0 0.6
EROA (mm2) 11 2
(n 6)
6 3
(n 6)
MR volume (mL/beat) 11.1 1.9
(n 6)
7.1 3.3
(n 6)
MR area (cm2) 3.4 2.1 3.6 1.3
MR/LA area ratio (%) 26 12 32 8
Annular area (cm2) 4.9 0.7
(n 6)
4.7 0.6
Peak MV gradient (mm Hg) 1.08 0.51 0.84 0.30
S-LMA dimension, ED (cm) 2.3 0.3 2.4 0.2
S-LMA dimension, ES (cm) 2.3 0.2 2.4 0.2
C-CMA dimension, ED (cm) 2.8 0.3 2.8 0.3
C-CMA dimension, ES (cm) 2.9 0.3 2.8 0.2
S-LLV dimension, ED (cm) 4.8 0.2 4.1 0.4
S-LLV dimension, ES (cm) 4.5 0.3 3.9 0.5
C-CLV dimension, ED (cm) 4.7 0.6 4.8 0.6
C-CLV dimension, ES (cm) 4.3 0.6 4.3 0.5
3-D echo findings
LVEDV (mL) 82 14 70 28
LVESV (mL) 65 14 54 23
SW (gm) 14.9 4.7 14.3 4.7
EF (%) 21.8 12.2 23.8 11.0
2-D, 2-dimensional; 3-D, 3-dimensional; MR, mitral regurgitation; TR, tricusp
MR area, MR jet area; MR/LA area ratio, ratio of MR jet to left atrial area
mitral annular commissure-commissure; S-LLV, left ventricular septal-late
commissure-commissure plane at midpapillary muscle level; MV, mitral v
stroke work; EF, ejection fraction.
Some results were not included because the requested measurements w
*P  .05 vs presizing.
†P  .05 vs baseline closed-chest.
‡P  .05 vs presizing.
§P  .05 vs postsizing.
P  .05 vs open-chest.
¶P  .05 vs presizing.cally significantly at postsizing. There were no significant
1072 The Journal of Thoracic and Cardiovascular Surgery ● Aprchanges in mean AoP and systolic LVP chronically. The
heart rate increased at terminal closed-chest (100 20 beats
per minute to 116 18 beats per minute; P .046), and the
heart rate at terminal open-chest increased significantly
compared with pre- and postsizing. The LAP at terminal
open-chest decreased significantly compared with pre- and
postsizing. In other hemodynamic parameters, there were no
significant differences between presizing and postsizing and
baseline closed-chest and terminal closed-chest. There were
no significant differences between terminal open-chest and
terminal subvalvular chord-cut and between presizing and
subvalvular chord-cut in all hemodynamic parameters (Ta-
ation Terminal
Postsizing
(n  7)
Closed-
chest
(n  6)
Open-
chest
(n  6)
Subvalvular
chord-cut
(n  6)
0.7 0.8* 0.8 0.8† 1.9 0.7‡,§ 3.6 0.8
2.4 1.3 2.3 0.4 2.6 0.5 2.9 0.7
1.0 0.6 0.7 0.8 1.0 0.7 0.8 0.8
1 1*
(n 6)
3 0.4†
(n 5)
7 4§
(n 5)
10 2
(n 5)
2.6 2.2*
(n 6)
3.0 1.1† 7.3 2.9
(n 5)
10.9 3.3
(n 5)
1.0 0.4* 1.1 0.8† 1.9 1.2 5.9 2.1
10 4* 11 8† 19 13 48 16
3.3 0.5* 4.4 0.1
(n 5)
4.3 0.3§
(n 5)
5.4 0.6¶
0.82 0.46 0.55 0.27 0.89 0.52 0.94 0.20
1.5 0.3* 1.8 0.1† 2.1 0.3§ 2.3 0.2
1.6 0.2* 1.8 0.2† 2.0 0.2‡,§ 2.4 0.2
2.6 0.5 2.7 0.3 2.8 0.2 2.8 0.3
2.6 0.5 2.8 0.3 3.0 0.3 3.0 0.3
2.4 0.2* 3.3 0.4† 3.3 0.5‡,§ 4.2 0.4
2.4 0.3* 3.4 0.5† 3.3 0.4‡,§ 4.0 0.5
5.3 0.5* 5.1 0.4 5.3 0.5 5.3 0.6
4.6 0.5 4.6 0.4 4.7 0.4 4.4 0.5
46 19* 75 16 58 12 65 10
30 20* 59 17 44 12 48 12
13.4 4.7 16.0 4.8 13.4 3.5 16.4 3.6
38.4 19.7 21.6 7.7 24.0 6.8 26.7 9.6
urgitation; AR, aortic regurgitation; EROA, effective regurgitant orifice area;
A, mitral annular septal-lateral; ED, end-diastole; ES, end-systole; C-CMA,
ension at midpapillary muscle level; C-CLV left ventricular dimension at
LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; SW, LV
ot taken during the study or images were poor.plant
id reg
; S-LM
ral dim
alve;
ere nble 2).
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PAt the time of autopsy, there were no injuries identified
to the papillary muscles, MV apparatus, or main coronary
artery and vein branches. The epicardial pads were firmly
seated on the tissue with no evidence of erosion. Examina-
tion of downstream organs revealed no infarction or emboli.
There was no thrombosis on the expanded polytetrafluoro-
Figure 3. MR decreased significantly from 2.9  0.7
significantly from 2.5  0.8 at baseline closed-chest
subvalvular chord was cut, MR increased significantly
difference between presizing and subvalvular chord-c
Figure 4. Mitral annular septal-lateral (S-LMA) dimen
acutely (from 2.4 0.2 cm at presizing to 1.5 0.3 cm a
was maintained (from 2.3  0.3 cm at baseline closed
There was significant increase from 1.5  0.3 cm at po
After cutting the Coapsys subvalvular chord, the S-LM
terminal open-chest. There was no significant changeethylene-covered subvalvular chords.
The Journal of ThoracicDiscussion
The Coapsys device reduced functional MR acutely and
chronically in the pacing-induced canine model. MR was
reduced in all animals; the mean MR decreased from 2.9 
0.7 at presizing to 0.7  0.8 at postsizing and was main-
tained for 8 weeks. MR immediately reappeared after cut-
presizing to 0.7  0.8 at postsizing. MR decreased
8  0.8 at terminal closed-chest. When the Coapsys
1.9  0.7 to 3.6  0.8, and there was no significant
s in end-diastolic. The S-LMA dimension decreased
tsizing; P .001). After 8 weeks follow-up, the change
st to 1.8  0.1 cm at terminal closed-chest; P  .025).
ing to 2.1  0.3 cm at terminal open-chest (P  .001).
ension increased significantly compared with that at
een presizing and subvalvular chord-cut.at
to 0.
from
ut.sion
t pos
-che
stsiz
A dim
betwting the Coapsys subvalvular chord. The S-LMA dimension
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(Figure 4). Timek and associates16 determined that a 22%
10% reduction in mitral annular septal-lateral dimension
abolished acute ischemic MR, and in their procedure, the
3-dimensional saddle shape of the annulus remained intact.
Figure 5. Mitral annular commissure-commissure
TABLE 2. Hemodynamics
Baseline
closed-chest
(n  7)
Implantation
Presizing
(n  7)
Post
(n
HR (beats/min) 100 20 92 10 92
COSG (L/min) 1.88 0.48 NA N
COFP (L/min) NA 1.71 0.55 1.63
SVSG (mL) 19.5 6.5 NA N
SVFP (mL) NA 19.2 8.3 18.4
LAPm (mm Hg) NA 16.5 5.8 15.5
LVPsys (mm Hg) 88 13 91 20 86
LVPed (mm Hg) 22.6 8.8 18.2 6.9 17.4
dP/dtmax (mm Hg/s) 980 309 910 317 890
dP/dtmin (mm Hg/s) 1042 325 986 326 975
AoPm (mm Hg) 81 13 77 20 73
SVR (dynescm5) 3163 609 3376 1238 3238
PAPm (mm Hg) 25.0 9.2 20.9 9.6 19.4
PVR (dynescm5) 327 151 236 257 214
PCWP (mm Hg) 18.0 8.0 NA N
CVP (mm Hg) 8.6 3.1 9.4 2.6 9.8
HR, Heart rate; COSG, cardiac output measured by thermodilution metho
measured by thermodilution method; SVFP, stroke volume measured by a
LVPed, LV end-diastolic pressure; SW, LV stroke work calculated by SV
dP/dtmin minimum negative rate of change of LV pressure; AoPm mean aort
pressure; PVR, pulmonary vascular resistance; PCWP, pulmonary capillar
*P  .05 vs presizing.
†P  .05 vs baseline closed-chest.
‡P  .05 vs presizing.
§P  .05 vs postsizing.The Coapsys device created a 21%  3% reduction of
1074 The Journal of Thoracic and Cardiovascular Surgery ● AprS-LMA dimension at end-systole in this chronic animal
study. The annular head of the posterior pad was located at
the mitral annular level and worked to reduce the S-LMA
dimension. This effect on the MR is the same as what Timek
and associates16 reported. The reduction of the S-LMA di-
MA) dimensions were unchanged in end-diastole.
Terminal
Closed-chest
(n  6)
Open-chest
(n  6)
Subvalvular chord-cut
(n  6)
116 18† 103 10‡§ 99 10
1.91 0.35 NA NA
9 NA 2.34 0.72 2.52 0.87
17.0 4.7 NA NA
NA 22.7 6.7 25.0 7.0
NA 12.5 2.6‡,§ 12.9 2.1
* 98 16 88 6 89 5
22.1 8.0 15.6 3.8 16.4 3.5
6 1099 287 888 84 869 169
4 1257 307 1003 154 951 151
* 88 18 69 6 71 5
69 3482 1418 2345 1224 2290 1277
22.6 8.7 18.7 3.5 20.1 2.7
1 169 97 248 159 277 198
19.6 10.1 14.1 3.0 14.9 2.2
10.1 2.5 9.2 1.4 9.5 1.3
FP, cardiac output measured by aortic flow probe; SVSG, stroke volume
ow probe; LAPm, mean left atrial pressure; LVPsys, LV systolic pressure;
V pressures; dP/dtmax, maximum positive rate of change of LV pressure;
ssure; SVR, systemic vascular resistance; PAPm, mean pulmonary arterial
ge pressure; CVP, central venous pressure.(C-Csizing
 7)
 10
A
 0.4
A
 7.7
 4.6
 18
 6.7
 31
 29
 18
 10
 8.3
 24
A
 3.0
d; CO
ortic fl
and L
ic pre
y wedmension was maintained for 8 weeks. The C-CMA dimen-
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Psion was unchanged at both end-diastole and end-systole.
This becomes important when one considers work by other
authors (such as Miller17), who suggest that the most im-
portant surgical goal in repairing the valve is to reduce and
fix the mitral annular dimension in the S-L axis and not
necessarily the C-C axis.
On the other hand, some groups have suggested ventric-
ular shape changes including papillary muscle repositioning
should be used to reduce functional MR.5,18,19 Surgical LV
remodeling was effective in reducing ischemic MR in an
animal infarct model.5 Also in animals, an external device
that repositioned papillary muscles reduced MR without
compromising LV function in an ischemic MR model.18
Menicanti and associates19 reported that papillary muscle
imbrication in patients undergoing ventricular reconstruc-
tion surgery reduced functional MR, which supports the
concept of LV reconstruction surgery used to reduce MR.
We believe that both annular reduction and papillary muscle
repositioning will create the most ideal, chronically effec-
tive treatment for functional MR. In accordance with this
belief, we employed a novel device to treat functional MR.
The posterior pad of the Coapsys device has two heads: one
to move the mitral annulus, the other to reposition the
papillary muscles.
From terminal closed chest to terminal open chest, MR
grade, EROA, MR volume, MR area, MR/LA area ratio,
end-diastolic S-LMA, and end-systolic S-LMA increased and
LVEDV and LVESV decreased. The significant decrease in
volume is likely due to hemodynamic changes caused by
opening the chest, freeing the heart of surrounding adhe-
sions, and redistributing circulating volume, which in turn
results in a reduction of annular change induced by the
device and the commensurate increase in MR indices. Also,
there is a possibility that this manipulation moved the Co-
apsys device. Additionally, continued pacing for 8 weeks
after implantation may have led to progressive LV dysfunc-
tion and MR. We cut the Coapsys subvalvular chord to
verify that maintenance of the valve competency was due to
the device. After cutting the Coapsys subvalvular chord, all
parameters regarding MR, which were improved by the
Coapsys device, returned to baseline. The mitral annular
and LV geometric changes also returned to the presizing
condition. These results suggest that the Coapsys device
maintained the reduction of functional MR.
The goal of the procedure was to mechanically coapt the
MV leaflets by changing the MV annular dimensions and
papillary muscle position. This fact was reflected in the
reduced MR measured by echocardiography, the primary
end point of this study. Echocardiographic reduction of MR
is, of course, also the clinical standard for judging MV
repair. We also secondarily sought to determine if there
were hemodynamic changes associated with this MR reduc-
tion. The methodologies of this type of hemodynamic mea-
The Journal of Thoracicsurement are more difficult to analyze and some conflict
exists between the results obtained by COSG, COFP, and
those calculated by 3-D echo volumetrics. By direct LAP
measurement, there was a significant reduction in LAP
(from 16.5  5.8 mm Hg at presizing to 12.5  2.6 mm Hg
at terminal open-chest, P  .022). Also, COFP increased
from 1.71  0.55 L/min at presizing to 2.34  0.72 L/min
at terminal open-chest but did not reach significance.
Whether these are accurate observations, or even important,
are different questions. Not all patients with cardiomyopa-
thy undergoing MV repair have an immediate improvement
in hemodynamic parameters. Heart failure is more complex
than just measurements of forward cardiac output. Also,
unlike the Myosplint (a completely different device and
concept),20,21 we were treating MR and so we did not try to
obtain major changes in ventricular size or dimensions.
There were, however, significant reductions in acute LV
volumes. Nevertheless, as with all such animal experimental
work, we need a careful randomized clinical study in a
much larger population to sort through the clinical benefits
of increasing MV coaptation and decreasing MR.
Study Limitations
In this animal study, we used the rapid ventricular pacing-
induced functional MR model with LV dysfunction. In this
model, there were usually 2 MR jets: a lateral and a medial
jet. This is similar to the pattern seen in human ischemic
cardiomyopathy (separated jets), whereas most patients
with idiopathic dilated cardiomyopathy have a single central
MR jet.8 The effect of the Coapsys device may be different
in these patients. We continued rapid pacing at 190 beats per
minute for 8 weeks after implantation, so somewhat mild or
moderate remodeling might have occurred during that time.
There were some inconsistencies in measurements be-
tween the COSG or COFP and the cardiac output calculated
from 3-D echo-derived LVEDV, LVESV, and 2-D echo-
derived MR volume. These inconsistencies are probably
due to the limitation of volumetric analysis using 3-D echo.
The 3-D echo data were shown to give estimates of LV
volume changes with this device.
Anatomic measurements, including depth of coaptation
and length of coaptation surface, would probably be a much
more accurate way to judge how much to tighten the device
rather than merely by interpreting color Doppler echo, and
that is certainly something that will be looked at carefully in
the clinical cases.
In conclusion, the Coapsys device reduced functional
MR and improved parameters regarding MR acutely and
chronically. In addition, we did not observe any negative
impact on hemodynamic function in this animal model. The
Coapsys device may be a promising new therapy for func-
tional MR, and clinical trials are under way.
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Discussion
Dr Farzan Filsoufi (New York, NY). Fifty-two years ago, the
pioneering cardiac surgeon, Charles Bailey, published a paper on
the surgical treatment of mitral insufficiency on a beating heart
using a strip of pericardium passed through the ventricle in a
fashion similar to that of this novel device. This places this
interesting study in historical context.
To understand the potential applicability of this device to
patients with mitral regurgitation secondary to ischemic heart
disease or dilated cardiomyopathy, it is important to emphasize the
pathophysiology of this condition. These patients have restricted
leaflet motion during systole resulting from ventricular dilatation
and papillary muscle displacement. This corresponds to type IIIb
dysfunction in Carpentier’s functional classification of MR. Most
patients also have some degree of secondary annular dilatation,
primarily in the septolateral dimension. This annular dilatation is
an important factor in the pathogenesis and progression of type
IIIb mitral regurgitation.
We believe the current standard of care for this condition is a
downsized remodeling annuloplasty, which reshapes the annulus
and increases the surface of coaptation by decreasing the septolat-
eral dimension. Because it only treats the annular component and
not the ventricular component of the dysfunction, the remodeling
annuloplasty technique is associated with a small incidence of
residual or recurrent mitral regurgitation.
The Coapsys device is unique in that it attempts to address both
the annular and ventricular components of type IIIb MR. This is a
well-designed and well-executed study in a difficult animal model
with interesting results.
I have the following questions for you. My first question relates
to durability. Although you demonstrate a significant reduction in
MR, this decrease did not correlate with expected anatomic find-
ings. For example, on 2-D echocardiography, the mitral valve area
and the septolateral dimension actually increased by 33% and 20%
over the 2-month study period. This inconsistency between the
physiologic correction of the MR and the anatomic findings should
be addressed. Are you concerned about this early increase in valve
area and septolateral dimension and its potential impact on the
long-term durability of the procedure?
My next question relates to your technique of intraoperative
sizing. You rely on intraoperative echo to size the device. How-
ever, our group and others have clearly documented the down-
grading of type IIIb MR by intraoperative echocardiography as a
result of downloading effects of general anesthesia. Do you feel
that anatomic measurements such as septolateral dimension and
coaptation depth and length would be more appropriate parameters
for sizing in the clinical setting?
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PMy third question relates to the clinical indications for the
device. There is a broad spectrum of patients with type IIIb MR
with regard to the severity of mitral regurgitation and the degree of
left ventricular dilatation. Which patients within this spectrum do
you feel are likely to have a successful, durable outcome with this
device? Specifically, do you believe that it will work as sole
therapy for patients with severe MR and dilated ventricles or do
you see it as an adjunct to annuloplasty in these patients?
Dr McCarthy. First, we assess carefully all of the changes that
we see regarding durability. One explanation for some of the
differences in measurements—which, by the way, were only about
3 mm—is that some of those measurements were made in the acute
setting with the chest open, versus later measurements with the
chest closed. So there are certainly differences in loading condi-
tions. Also, measurements are influenced by the difference in echo
techniques in that the measurement of the annular area was by
short axis, the measurement of the septolateral by long axis, and
the commissure-to-commissure measurement by 2-chamber views.
So it is hard in 2-D echoes to really recreate the total annular areaThe Journal of Thoracicent views. Furthermore, this is a pacing model of heart failure that
we had developed a few years ago, and there is ongoing pacing at
a rate of 190 beats per minute. So we expect that there would be
some continued remodeling during that time, which may account
for some of the small changes. Nevertheless, durability is the most
important issue for the clinical trials.
In terms of the technique, I completely agree that anatomic
measurements, including coaptation depth and length, would prob-
ably be a much more accurate way to judge how to place the
device than merely by interpreting color Doppler echo. This is
certainly something that will be looked at carefully in the clinical
cases.
In terms of the clinical indications, I don’t know yet exactly
what role this is going to have. Coapsys just recently began a
randomized clinical trial in the United States with groups of
patients undergoing coronary artery bypass grafting (CABG) with
ring annuloplasty, patients undergoing CABG alone, and CABG
with the Coapsys device. So we will be looking at how this holds
up in patients with ischemic cardiomyopathy and then we canand correlate it to the other 2 measurements because of the differ- determine the proper role for Coapsys.and Cardiovascular Surgery ● Volume 127, Number 4 1077
